Fig. 4
From: IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia
FLT3-ITD mutations associate with elevated IL1RAP expression. A IL1RAP transcript levels in NKt-AML and other specimens of the Leucegene AML RNA-sequencing cohort (n = 691). P value calculated with Wilcoxon test. B Enrichment analysis of specimen characteristics in top 20% specimens with highest IL1RAP levels compared to other specimens of the Leucegene AML RNA-sequencing cohort. C Scatter plot of IL1RAP and CD34 (log10 TPM + 1). FLT3-ITD mutated samples are shown in red. D Transcriptomic analysis of IL1RAP expression in NKt-AML, FLT3-ITD AML and samples from other AML subgroups of the Leucegene AML RNA-sequencing cohort. P values were calculated using the Wilcoxon test. E IL1RAP protein intensity measured by surface proteomics in NKt-AML, FLT3-ITD AML and samples from other AML subgroups of the Leucegene AML surfaceome cohort. P values were calculated using the Wilcoxon test. F Percentage of IL1RAP-expressing blasts determined by flow cytometry in NKt-AML, FLT3-ITD and FLT3 WT AML specimens. Bars represent medians. P values were calculated using the Wilcoxon test. G Multivariate regression analysis of IL1RAP transcript levels, regarding status of NPM1, DNMT3 A, FLT3-ITD, RUNX1, and TET2 mutation and all mutation combination. P values were calculated using the Wilcoxon test